00:46 , Aug 4, 2018 |  BioCentury  |  Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
19:59 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Halozyme's PEGPH20 leads to worse OS in first-line pancreatic cancer

Halozyme Therapeutics Inc. (NASDAQ:HALO) reported that PEGPH20 plus modified FOLFIRINOX chemotherapy led to worse overall survival (OS) compared with chemotherapy alone in the Phase Ib/II S1313 trial to treat previously untreated metastatic pancreatic cancer. The...
20:05 , Jan 17, 2018 |  BC Extra  |  Clinical News

First-line pancreatic cancer readout sinks Halozyme shares

Halozyme Therapeutics Inc. (NASDAQ:HALO) slipped $1.76 to $17.98 Wednesday after reporting that PEGPH20 plus modified FOLFIRINOX chemotherapy led to worse overall survival (OS) compared with chemotherapy alone in the Phase Ib/II S1313 trial to treat...
00:18 , Dec 22, 2017 |  BC Week In Review  |  Company News

Alexion licenses Halozyme's drug delivery tech

Halozyme Therapeutics Inc. (NASDAQ:HALO) granted Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) a license to use its Enhanze technology to develop subcutaneous formulations of therapies against up to four targets, including a new formulation of ALXN1210. Halozyme will...
19:04 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Halozyme starts Phase Ib/II of PEGPH20 plus Tecentriq

In October, Halozyme Therapeutics Inc. (NASDAQ:HALO) began the Phase Ib/II HALO-110-101 trial to evaluate PEGPH20 in combination with standard chemotherapy with or without Tecentriq atezolizumab to treat previously untreated, unresectable, locally advanced, or metastatic cholangiocarcinoma...
19:37 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

BioTime reports additional data for Renevia facial lipoatrophy device

BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX) reported long-term data from a European pivotal trial of Renevia to treat HIV-associated lipoatrophy, which the company said is a severe form of lipoatrophy characterized by the pathological loss of...
21:09 , Sep 15, 2017 |  BC Week In Review  |  Company News

Halozyme increases revenue guidance on BMS, Roche deals

Halozyme Therapeutics Inc. (NASDAQ:HALO) raised its 2017 revenue guidance after announcing two separate licensing deals for its Enhanze drug-delivery technology with Bristol-Myers Squibb Co. (NYSE:BMY) and Roche (SIX:ROG; OTCQX:RHHBY). The biotech now expects 2017 revenues to...
22:21 , Sep 14, 2017 |  BC Extra  |  Company News

Halozyme increases revenue guidance on BMS, Roche deals

Halozyme Therapeutics Inc. (NASDAQ:HALO) jumped $2.80 (21%) to $15.98 and raised its 2017 revenue guidance on Thursday after announcing two separate licensing deals for its Enhanze drug-delivery technology with Bristol-Myers Squibb Co. (NYSE:BMY) and Roche...
01:20 , Apr 6, 2017 |  BC Week In Review  |  Clinical News

PEGPH20: Ph Ib/II S1313 data

Halozyme said it was informed by the Southwest Oncology Group that the U.S. Phase Ib/II S1313 trial evaluating 3 µg/kg IV PEGPH20 every 2 weeks plus modified FOLFIRINOX chemotherapy vs. modified FOLFIRINOX alone in previously...
22:37 , Mar 27, 2017 |  BC Extra  |  Clinical News

Novartis scientists extend half-life of ocular therapies

In a paper published in Nature Communications, researchers from the Novartis Institutes for BioMedical Research at Novartis AG (NYSE:NVS; SIX:NOVN) said they had developed a method to extend the half-life of therapies by three- to...